Caris Life Sciences vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Caris Life Sciences provides comprehensive molecular profiling of tumors to guide cancer treatment decisions, with one of the largest oncology biomarker databases.
About
Caris Life Sciences is a precision oncology company founded in 1998 and headquartered in Irving, Texas, that provides comprehensive molecular profiling tests used by oncologists to select personalized cancer treatments. The company's flagship test Molecular Intelligence analyzes tumors using whole transcriptome sequencing, whole exome sequencing, and protein expression to identify biomarkers that predict response to specific therapies including targeted drugs and immunotherapies. Caris has built one of the largest real-world oncology molecular databases, with profiles from hundreds of thousands of patient tumors that are used for research, drug development partnerships, and AI model training. The company serves oncologists, cancer centers, and pharmaceutical companies conducting biomarker-driven clinical trials. Caris has raised over $1B and operates CLIA-certified laboratory facilities in Phoenix and Irving. The company's database and AI capabilities have attracted partnerships with pharmaceutical companies seeking to identify patient populations most likely to respond to novel therapies. Caris positions itself at the intersection of clinical diagnostics and drug development infrastructure, generating value both from patient care and from the insights its large clinical database enables.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.